Caroline J. Loew
President and CEO
Solstice Oncology
Neoadjuvant immuno-oncology therapies designed to improve cure rates
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Solstice Oncology is a Boston clinical-stage immuno-oncology company developing porustobart, an engineered CTLA-4 antibody, in combination with anti–PD-1 therapy for neoadjuvant treatment of early-stage cancers, beginning with MSS stage III colon cancer. Led by CEO Caroline J. Loew. Public site: solsticeoncology.com.
- Website
- solsticeoncology.com
- Location
- Boston, MA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Porustobart — Engineered CTLA-4 antibody for neoadjuvant immuno-oncology · Other